influenza
virus
caus
recurr
season
epidem
pandem
respiratori
infect
lead
million
million
case
sever
ill
death
worldwid
everi
especi
infant
young
children
pregnant
women
elderli
patient
weaken
immun
system
influenza
like
caus
seriou
complic
therefor
world
health
organ
identifi
influenza
major
public
health
furthermor
emerg
spread
new
high
pathogen
influenza
variant
pose
critic
challeng
global
health
includ
swineorigin
china
novel
avian
influenza
viru
caus
nationwid
outbreak
januari
june
estim
averag
risk
fatal
associ
infect
approxim
much
higher
sar
although
viral
neuraminidas
na
inhibitor
ion
channel
blocker
wide
use
seriou
side
effect
low
efficaci
report
emerg
drug
resist
strain
influenza
rnadepend
rna
polymeras
rdrp
compos
three
subunit
pa
promis
altern
target
novel
antiinfluenza
drug
discoveri
research
essenti
transcript
replic
viru
gene
conserv
among
differ
type
influenza
transcript
rdrp
synthes
cap
polyadenyl
mrna
use
cap
rna
primer
replic
rdrp
gener
complementari
rna
crna
replic
intermedi
serv
templat
synthesi
new
copi
viral
rna
vrna
influenza
viru
polymeras
requir
larg
number
host
cell
factor
engag
viral
rna
transcript
replic
interact
influenza
polymeras
host
cell
factor
identifi
divers
method
genomewid
rna
interfer
rnai
proteom
systemat
immunoprecipit
host
factor
pact
doublestrand
rnabind
protein
also
known
activ
cellular
dsrnadepend
protein
kinas
pact
involv
interact
influenza
viru
iav
host
cell
substanti
enhanc
rigi
activ
phosphoryl
eukaryot
translat
initi
factor
alpha
induc
ifn
type
respons
suppress
nonstructur
influenza
viru
protein
recent
research
emphas
iav
infect
pact
exert
antivir
activ
primarili
interact
inhibit
iav
polymeras
demonstr
pact
associ
pa
compromis
pact
iavinfect
cell
led
enhanc
vrna
transcript
replic
product
addit
vrna
replic
increas
knock
pact
cell
ifninsuffici
vero
iridoid
glycosid
princip
bioactiv
compon
fructu
gardenia
antivir
antiinflammatori
characterist
use
gener
chines
herbal
medicin
centuri
sever
asian
report
geniposid
main
iridoid
glycosid
compound
extract
gardenia
jasminoid
j
elli
fruit
effect
block
cell
damag
induc
pandem
influenza
viru
allevi
virusinduc
acut
lung
previou
studi
demonstr
fructu
gardenia
iridoid
glycosid
extract
ige
exhibit
antivir
effect
influenza
viru
subtyp
vitro
rna
replic
influenza
viru
inhibit
ige
dosedepend
manner
underli
mechan
yet
deciph
present
studi
first
determin
protect
effect
fructu
gardenia
iridoid
glycosid
extract
ige
cell
mice
infect
influenza
viru
next
investig
whether
ige
could
inhibit
vrna
replic
host
factor
pact
activ
evalu
level
viru
replic
protein
express
pact
phosphoryl
cell
level
pact
pkr
mous
lung
tissu
addit
assess
whether
ige
inhibit
influenza
viru
replic
pactdepend
manner
measur
rna
polymeras
activ
influenza
viru
cell
pact
protein
express
knock
sirna
present
studi
antiinfluenza
viru
activ
ige
measur
visual
cpe
mdck
cell
show
signific
cytopath
effect
round
slough
h
post
infect
ige
obvious
inhibit
influenza
viru
fig
evalu
protect
effect
ige
mdck
cell
induc
influenza
viru
cell
viabil
examin
mtt
assay
moreov
mdck
cell
viru
titr
analys
plaqu
format
assay
viru
control
group
cell
viabil
dramat
decreas
ige
treatment
significantli
increas
cell
viabil
concentr
respect
fig
viru
titr
mdck
cell
infect
influenza
viru
markedli
decreas
ige
treatment
dosedepend
manner
fig
find
indic
influenza
viru
sensit
ige
treatment
vitro
current
studi
antiinfluenza
activ
ige
vivo
measur
use
pi
irpi
pi
calcul
assess
lung
oedema
mice
viru
control
group
present
increas
pi
compar
present
normal
control
group
compar
viru
control
group
group
treat
ige
dose
mgkg
present
significantli
decreas
dosedepend
pi
fig
addit
group
treat
ige
show
substanti
inhibit
pi
activ
rate
pulmonari
index
irpi
decreas
mgkg
dose
respect
fig
evalu
protect
efficaci
ige
lethal
influenza
challeng
chang
bodi
weight
reduct
mortal
prolong
surviv
time
estim
balbc
mice
viru
control
group
weight
mice
mildli
increas
day
postinfect
day
postinfect
weight
mice
decreas
minimum
valu
day
postinfect
weight
mice
visibl
increas
ige
treatment
restor
bodi
weight
loss
day
postinfect
fig
fourteen
day
infect
mice
viru
control
group
die
mortal
mortal
significantli
decreas
ige
treatment
dose
mgkg
mice
group
compar
viru
control
group
moreov
ige
treatment
protect
mice
death
dose
mgkg
respect
fig
addit
ige
treatment
mgkg
dramat
increas
surviv
time
mice
day
compar
surviv
time
mice
viru
control
group
fig
explor
inhibitori
effect
ige
influenza
viru
replic
rel
valu
viru
replic
mdck
cell
analys
h
postinfect
viru
replic
increas
rapidli
h
postinfect
ige
notabl
inhibit
replic
influenza
viru
dosedepend
manner
five
time
point
postinfect
fig
ige
show
greatest
inhibitori
effect
viru
replic
h
postinfect
viru
inhibit
rate
concentr
respect
fig
result
demonstr
ige
significantli
suppress
viru
replic
mdck
cell
pact
function
activ
rigi
facilit
viral
induct
type
ifn
verifi
type
ifn
respons
induc
iav
infect
level
pact
pkr
lung
tissu
evalu
elisa
five
day
mice
inocul
influenza
viru
level
pact
pkr
remark
pronounc
henc
iav
infect
induc
type
ifn
antivir
respons
activ
pact
pkr
ige
treatment
significantli
decreas
product
dose
mgkg
dosedepend
manner
fig
furthermor
shown
fig
fig
elev
level
pact
pkr
lung
tissu
iavinfect
mice
depress
ige
administ
dose
mgkg
follow
activ
pact
pkr
phosphoryl
substrat
assess
effect
ige
pact
activ
pact
express
phosphoryl
cell
detect
western
blot
h
postinfect
pact
express
markedli
increas
h
postinfect
accordingli
phosphoryl
h
iav
infect
ige
treatment
appar
suppress
pact
express
dosedepend
manner
three
time
point
postinfect
fig
notabl
phosphoryl
inhibit
ige
treatment
time
point
fig
result
indic
overactiv
pact
induc
iav
suppress
ige
treatment
describ
demonstr
ige
suppress
viru
replic
pact
overactiv
clarifi
whether
ige
inhibit
viru
replic
pactdepend
manner
iav
polymeras
activ
determin
cell
pact
protein
express
knock
sirna
pact
deplet
rna
polymeras
activ
robust
henc
viru
replic
catalys
iav
polymeras
enhanc
knockdown
pact
pactdefici
cell
suppress
iav
polymeras
activ
remark
robust
ige
treatment
dose
pact
knock
result
suggest
ige
might
inhibit
viru
replic
pactdepend
manner
fig
influenza
viru
caus
sever
respiratori
ill
annual
especi
elderli
immunocompromis
individu
lead
complic
hospit
case
even
current
use
firstlin
drug
prevent
treatment
influenza
neuraminidas
inhibitor
nai
repres
howev
rapid
emerg
spread
resist
oseltamivir
creat
urgent
need
develop
novel
antiinfluenza
drug
differ
mechan
studi
report
iridoid
glycosid
extract
fructu
gardenia
possess
antivir
activ
influenza
includ
strain
pandem
vitro
despit
great
therapeut
potenti
ige
abil
suppress
viru
replic
improv
innat
immun
function
poorli
understood
present
studi
result
demonstr
ige
possess
potent
antivir
properti
influenza
viru
could
allevi
cell
damag
reduc
plaqu
format
induc
subtyp
influenza
viru
noncytotox
concentr
dosedepend
manner
vitro
pathogen
influenza
viru
caus
respiratori
tract
infect
develop
sever
influenza
pneumonia
lead
acut
pulmonari
injuri
ali
acut
respiratori
distress
syndrom
ard
even
death
studi
success
establish
mous
model
iav
pneumonia
death
mice
infect
influenza
viru
mous
model
iav
pneumonia
ige
exhibit
inhibitori
effect
pulmonari
index
indic
ige
protect
lung
tissu
influenzainduc
injuri
note
mous
death
model
chang
bodi
weight
reduc
mortal
prolong
surviv
time
suggest
ige
treatment
suffici
protect
rescu
mice
lethal
iav
infect
verifi
whether
ige
inhibit
viru
replic
express
influenza
gene
cell
determin
quantit
realtim
pcr
result
show
viru
replic
cell
increas
significantli
h
postinfect
particular
rel
valu
indic
viru
replic
sharpli
increas
h
postinfect
valu
viru
control
group
cell
control
group
cell
ige
administr
significantli
suppress
influenza
viru
replic
five
time
point
dosedepend
manner
result
indic
iav
lifecycl
ige
capabl
inhibit
viru
replic
propag
vitro
determin
whether
ige
affect
innat
immun
defenc
iav
level
pact
pkr
lung
tissu
iavinfect
mice
assess
type
interferon
ifni
key
compon
innat
antivir
respons
constitut
first
line
host
defenc
influenza
viru
activ
ifni
respons
requir
pact
interact
rna
polymeras
nonstructur
protein
influenza
influenza
viru
replic
depend
interact
virusencod
protein
host
factor
regul
pivot
aspect
cell
surviv
viru
recognit
replic
pathogen
host
report
pact
crucial
antivir
host
factor
mediat
activ
dsrnadepend
kinas
pkr
stimul
substanti
rigi
activ
induc
ifni
pact
coexpress
rigi
promot
activ
induc
iav
rnp
complex
outcom
iav
infect
depend
intric
interact
viru
host
iav
prevail
antivir
activ
ifn
insuffici
inhibit
iav
replic
accumul
vrna
rnp
result
overactiv
ifn
might
lead
develop
patholog
inflamm
contrast
ifn
prevail
iav
replic
suppress
eventu
current
studi
pkr
pact
level
remark
elev
lung
tissu
mice
infect
iav
result
indic
iav
infect
induc
ifni
respons
mice
pact
enhanc
activ
pkr
ifn
respons
find
consist
recent
report
ige
treatment
dose
mgkg
significantli
decreas
product
depress
elev
level
pact
pkr
lung
tissu
iavinfect
mice
find
reveal
ige
might
protect
iavinfect
mice
pneumonia
death
inhibit
overactiv
ifn
respons
induc
pact
respons
stress
signal
induc
viral
infect
four
mammalian
serinethreonin
kinas
phosphoryl
eukaryot
protein
translat
initi
factor
includ
hri
perk
among
kinas
ifniinduc
pkr
play
crucial
role
antivir
innat
immun
respons
influenza
viru
pactdepend
pkr
activ
lead
phosphoryl
result
arrest
translat
cellular
viral
mrna
effici
way
suppress
viru
verifi
activ
pact
induc
iav
infect
measur
pact
express
phosphoryl
infect
cell
h
postinfect
current
studi
pact
express
cell
increas
significantli
h
iav
infect
addit
phosphoryl
cell
dramat
increas
h
iav
infect
result
demonstr
iav
infect
led
pact
respons
activ
phosphoryl
find
gener
agreement
previou
furthermor
ige
treatment
markedli
inhibit
pact
express
dosedepend
manner
three
measur
time
point
post
infect
interestingli
phosphoryl
significantli
suppress
ige
treatment
four
time
point
result
indic
overactiv
pact
phosphoryl
induc
iav
suppress
ige
treatment
provid
evid
ige
exert
antiiav
activ
inhibit
overactiv
pactdepend
innat
immun
respons
pact
identifi
antivir
host
factor
interact
iav
polymeras
interact
pact
iav
polymeras
play
pivot
role
outcom
viru
infect
antivir
immun
respons
demonstr
pactdepend
activ
product
inhibit
three
subunit
iav
rnp
reconstitut
assay
knock
pact
iavinfect
cell
enhanc
vrna
product
subsequ
ifn
interest
might
interplay
pact
viral
molecul
herp
simplex
viru
type
protein
middl
east
respiratori
syndrom
coronaviru
merscov
nucleocapsid
ebola
viru
ebov
mous
hepat
viru
mhv
n
protein
influenza
viru
henc
pact
might
common
target
counteract
innat
immun
respons
induc
differ
virus
potenti
develop
new
broadspectrum
antivir
drug
investig
whether
ige
suppress
iav
replic
pactdepend
manner
pact
compromis
sirna
cell
cotransfect
four
plasmid
contain
np
pa
accord
result
dualluciferas
report
gene
assay
cell
transfect
pfluluc
show
low
rel
luciferas
activ
iav
rna
polymeras
contrast
cell
cotransfect
plasmid
contain
np
pa
fluluc
show
rel
high
rna
polymeras
activ
note
result
indic
knock
pact
enhanc
iav
polymeras
activ
find
consist
previou
studi
henc
viru
replic
catalys
iav
polymeras
enhanc
compromis
action
pact
identifi
antivir
host
factor
addit
ige
treatment
dose
show
rel
weak
suppress
effect
iav
polymeras
activ
pactknockdown
cell
collect
data
current
studi
demonstr
ige
treatment
might
inhibit
iav
replic
pactdepend
manner
conclus
research
indic
ige
suffici
allevi
cell
damag
suppress
iav
replic
vitro
protect
lung
tissu
iavinduc
injuri
mice
model
influenzainduc
pneumonia
rescu
mice
lethal
iav
infect
antiiav
effect
might
relat
disrupt
interplay
iva
polymeras
cellular
doublestrand
rnabind
protein
pact
prevent
overactiv
pactdepend
ifni
antivir
respons
induc
iav
infect
taken
togeth
find
reveal
new
facet
mechan
ige
action
influenza
viru
inhibit
iav
replic
pactdepend
manner
current
studi
might
pave
way
develop
new
antivir
agent
iav
experi
involv
live
influenza
virus
conduct
anim
biosafeti
level
laboratori
institut
chines
materia
medica
china
academi
chines
medic
scienc
first
powder
dri
fruit
kg
refluxextract
twice
ethanol
extract
combin
centrifug
next
supernat
fluid
vacuum
dri
remov
trace
alcohol
concentr
solut
dilut
water
mass
concentr
gml
filtrat
pass
macropor
resin
success
elut
water
ethanol
ethanol
elut
fraction
combin
dri
extract
sampl
sampl
store
dissolv
doubl
distil
water
time
use
puriti
geniposid
puriti
iridoid
glycosid
sampl
detect
uv
spectrophotometri
beij
gener
instrument
co
ltd
beij
china
influenza
viru
strain
provid
nation
institut
viral
diseas
control
prevent
chines
center
diseas
control
prevent
viru
stock
prepar
infect
specificpathogenfre
embryon
chicken
egg
merial
vital
laboratori
anim
technolog
co
ltd
beij
china
h
viru
titr
express
tissu
cultur
infect
dose
calcul
mdck
cell
reedmuench
mdck
cell
purchas
cell
center
institut
basic
medic
scienc
peke
union
medic
colleg
beij
china
cultiv
dmem
supplement
foetal
bovin
serum
penicillinstreptomycin
gibco
icr
mice
g
balbc
mice
g
obtain
vital
river
laboratori
anim
technolog
co
ltd
beij
china
acclim
standard
feed
water
follow
condit
temperatur
humid
experi
perform
complianc
rule
european
commun
guidelin
care
use
anim
studi
approv
ethic
committe
institut
chines
materia
medica
china
academi
chines
medic
scienc
mdck
cell
cultur
plate
densiti
cellsml
expos
strain
influenza
viru
h
infect
cell
incub
h
serial
dilut
ige
solut
final
concentr
ribavirin
use
posit
drug
control
final
concentr
mgml
incub
h
infect
cell
show
signific
cytopath
effect
cpe
distinguish
round
slough
inhibit
effect
ige
cpe
induc
influenza
viru
determin
mtt
assay
cell
viabil
express
percentag
cell
control
group
viru
titr
quantifi
plaqu
format
assay
present
neg
lg
tissu
cultur
infecti
dose
normal
control
group
virusinfect
control
sixti
icr
mice
g
male
femal
randomli
separ
six
group
group
ribavirin
treatment
group
mgkg
three
ige
treatment
group
base
administ
ige
dose
mgkg
mice
except
normal
control
group
infect
intranas
viral
suspens
influenza
concentr
time
median
lethal
dose
treatment
group
inocul
mice
success
given
daili
dose
ige
ribavirin
oral
day
begin
day
infect
mous
control
group
given
volum
distil
water
equal
ige
treatment
volum
day
mice
sacrif
bodi
weight
bw
lung
weight
lw
determin
calcul
pulmonari
index
pi
inhibitori
rate
pulmonari
index
irpi
pi
lw
g
bw
g
irpi
lw
viru
control
grouplw
treatment
group
lw
viru
control
grouplw
normal
control
group
lung
tissu
collect
subject
elisa
total
balbc
mice
randomli
distribut
five
group
mice
per
group
virusinfect
control
group
ribavirin
treatment
group
three
ige
treatment
group
mice
infect
influenza
viru
strain
solut
concentr
greater
intranas
instil
treatment
group
inocul
mice
success
given
ige
oral
dose
mlkg
mlkg
mlkg
treat
mgkg
ribavirin
daili
day
begin
infect
day
mous
control
group
receiv
volum
distil
water
equal
treatment
volum
bodi
weight
chang
determin
day
postinfect
surviv
mice
record
everi
day
consecut
day
protect
effect
lethal
challeng
determin
increas
bodi
weight
reduct
mortal
prolong
surviv
time
level
influenza
viru
replic
mdck
cell
detect
quantit
realtim
rtpcr
total
cellular
rna
extract
h
postinfect
trizol
reagent
invitrogen
usa
accord
manufactur
instruct
qrtpcr
assay
perform
use
onestep
sybr
primescript
rtpcr
kit
takara
japan
accord
manufactur
protocol
influenza
viru
protein
gene
forward
primer
revers
primer
gapdh
forward
primer
revers
primer
transcript
level
influenza
viru
gapdh
calcul
method
pcr
carri
use
quantit
pcr
instrument
thermo
usa
follow
condit
min
sec
follow
cycl
sec
sec
inhibitori
rate
viru
replic
rel
valu
viru
replic
treatment
group
rel
valu
viru
replic
viru
control
group
level
pact
pkr
mous
lung
tissu
detect
enzymelink
immunosorb
assay
elisa
kit
meilian
co
ltd
shanghai
china
follow
manufactur
instruct
cell
lyse
dissect
ripa
buffer
contain
proteas
inhibitor
proteas
phosphatas
inhibitor
h
postinfect
protein
total
protein
concentr
determin
use
bca
kit
ensur
equal
amount
sampl
protein
load
sdspage
gel
transfer
onto
nitrocellulos
membran
membran
incub
overnight
primari
antibodi
follow
protein
pact
abcam
usa
gapdh
cst
usa
cst
usa
subsequ
membran
incub
secondari
goat
antirabbit
igg
antibodi
h
room
temperatur
blot
develop
ecl
densiti
band
calcul
nih
imagej
softwar
first
cell
transfect
pact
sirna
forward
primer
revers
primer
h
next
four
plasmid
contain
rdrp
cdna
influenza
viru
pfluluc
cotransfect
cell
use
lipofectamin
transfect
kit
invitrogen
usa
accord
method
describ
previou
neg
control
group
pfluluc
transfect
cell
h
posttransfect
supernat
discard
subsequ
two
concentr
ige
ad
incub
h
final
luciferas
activ
detect
use
dualluciferas
report
assay
system
promega
usa
accord
manufactur
protocol
luminesc
intens
read
use
thermo
varioskan
flash
reader
usa
rel
luciferas
activ
calcul
base
ratio
renilla
luciferas
valu
firefli
luciferas
valu
statist
analysi
perform
use
graphpad
prism
softwar
system
data
present
mean
sem
standard
error
mean
test
use
analys
reduct
mortal
result
analys
oneway
analysi
varianc
anova
signific
differ
determin
bonferroni
test
p
valu
consid
signific
